As seen in Figure 4, this indeed was the case, and the expansion of CD62L− non-Treg CD4+ T in patients with SCCHN was accompanied by a significant concomitant decrease in the percent of CD4+CD25−CD62L+ cells. This evidence concerns the gene SELL and head and neck squamous cell carcinoma.